Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

Rhea-AI Summary

VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for April 9, 2025, at 10:00 AM ET, focusing on their Nu.Q® Cancer platform. Key executives including Chief Commercial Officer Gael Forterre, Chief Medical Officer Dr. Andrew Retter, and Chief Scientific Officer Dr. Jake Micallef will present.

The event will showcase findings from large independent studies supporting their Nu.Q® platform in cancer detection. Notably, recent research undergoing peer review indicates that the Nu.Q® Cancer test successfully detected multiple common cancers (lung, breast, prostate, colon, and liver) with an overall AUC of 86% and low false positive rates.

The company is targeting two significant market opportunities:

• The lung cancer market (screening, prognostication, and minimal residual disease) estimated at $4 billion
• The liquid biopsy market for multi-cancer early detection in the U.S., valued at approximately $20 billion

HENDERSON, Nev., March 27, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer. To register, click here.

This webinar will provide an overview following the completion of a number of large independent studies supporting the value of our Nu.Q® platform in cancer.

Mr. Forterre will provide an update on Volition's progress to commercialization through both licensing and direct and indirect sales.

Dr. Retter will focus on the potential role of Volition's Nu.Q® assays in the management of lung cancer: from screening to aiding treatment selection at diagnosis and monitoring treatment response, minimal residual disease and disease progression.

The Total Annual Accessible Market for lung cancer (screening, prognostication and identification of minimal residual disease) is estimated to be approximately $4 billion, representing a significant revenue opportunity for Volition¹.

Dr Micallef will discuss findings published in a paper currently undergoing peer review and accessible on MedRXIV, which reported that the Nu.Q® Cancer test detected common cancer diseases, including cancers of the lung, breast, prostate, colon and liver (overall AUC=86%) with very low false positive rates.

We are excited to publish this further validation of our Nu.Q® platform; it represents a potential opportunity to disrupt the $20 billion Total Annual Accessible Market for liquid biopsy for multi-cancer early detection in the U.S.¹.

A live question and answer session will follow the formal presentations.

 

1.Data on file, Volition Total Addressable Market model.

 

About Gael Forterre

Gael Forterre is the Chief Commercial Officer of Volition, joining the team in 2021. He is focused on building a strong commercialization plan and team to drive the extensive range of assays developed using the Nu.Q® platform. Gael has extensive experience investing in and scaling fast growing companies, most recently as CEO of Pathify. He is currently the non-executive chairman of Vahau.

Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles for over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.

About Dr. Andrew Retter

Andrew Retter, BSc (Hons), MBBS, FRCP, FRCPath (Haem), DICM is Consultant in Critical Care, ECMO & Thrombosis and also the Clinical Lead for Critical Care at one of the UK's largest hospitals in London, where he has worked as a  Consultant since 2014. He is also the Chief Medical Officer at Volition. Dr Retter has been involved in clinical trials and research studies and has published over 50 articles in peer-reviewed medical journals.

About Dr. Jake Micallef

Jake Micallef PhD, MBA is the Chief Scientific Officer and one of the founding scientists of Volition. He is an experienced scientist with expertise in research and development in diagnostics, both commercially and for the UK National Health Service and World Health Organization. Jake is the co-inventor and author of the patents surrounding Volition's Nucleosomics™ technology.

Jake received both his BSc in Biology and Chemistry and Ph.D. in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology from St Thomas' Hospital Medical School and his MBA from Imperial College Management School.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document.  Such website address is included in this document as an inactive textual reference only.

Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620

Investor Relations:
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com +1-212-915-2568

Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, the exercise of the milestone-linked warrants upon the achievement of such milestone events or otherwise prior to their expiration, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition's cost reduction measures, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.  Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content:https://www.prnewswire.com/news-releases/volition-to-host-virtual-investor-event-on-nuq-cancer-a-look-to-the-future-of-cancer-diagnostics-on-april-9-2025-302413141.html

SOURCE VolitionRx Limited

FAQ

When is VNRX hosting their Nu.Q® Cancer virtual investor event and who will present?

The virtual investor event is scheduled for April 9, 2025, at 10:00 AM ET, featuring presentations from Gael Forterre (CCO), Dr. Andrew Retter (CMO), and Dr. Jake Micallef (CSO).

What cancer detection accuracy has VNRX's Nu.Q® Cancer test demonstrated in recent studies?

The Nu.Q® Cancer test showed an overall AUC of 86% in detecting common cancers including lung, breast, prostate, colon, and liver, with very low false positive rates.

What is the market opportunity for VNRX's Nu.Q® platform in lung cancer diagnostics?

The Total Annual Accessible Market for lung cancer applications is estimated at $4 billion, covering screening, prognostication, and minimal residual disease identification.

How large is the potential market for VNRX's liquid biopsy technology in multi-cancer early detection?

The Total Annual Accessible Market for liquid biopsy in multi-cancer early detection in the U.S. is estimated at $20 billion.

What types of cancer can VNRX's Nu.Q® Cancer test detect?

The Nu.Q® Cancer test can detect common cancers including lung, breast, prostate, colon, and liver cancers.